WOOJUNG BIO Inc (215380) - Total Assets
Based on the latest financial reports, WOOJUNG BIO Inc (215380) holds total assets worth ₩89.80 Billion KRW (≈ $60.86 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 215380 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
WOOJUNG BIO Inc - Total Assets Trend (2016–2024)
This chart illustrates how WOOJUNG BIO Inc's total assets have evolved over time, based on quarterly financial data. Explore WOOJUNG BIO Inc (215380) long-term investment share to see how much of total assets are deployed in long-term investments.
WOOJUNG BIO Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
WOOJUNG BIO Inc's total assets of ₩89.80 Billion consist of 21.0% current assets and 79.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 4.2% |
| Accounts Receivable | ₩5.98 Billion | 6.3% |
| Inventory | ₩4.97 Billion | 5.3% |
| Property, Plant & Equipment | ₩51.58 Billion | 54.5% |
| Intangible Assets | ₩918.11 Million | 1.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how WOOJUNG BIO Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 215380 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: WOOJUNG BIO Inc's current assets represent 21.0% of total assets in 2024, a decrease from 100.0% in 2016.
- Cash Position: Cash and equivalents constituted 4.2% of total assets in 2024, down from 21.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2016.
- Asset Diversification: The largest asset category is property, plant & equipment at 54.5% of total assets.
WOOJUNG BIO Inc Competitors by Total Assets
Key competitors of WOOJUNG BIO Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
WOOJUNG BIO Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.56 | 0.36 | 1.78 |
| Quick Ratio | 0.30 | 0.24 | 1.54 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-13.85 Billion | ₩-21.69 Billion | ₩12.36 Billion |
WOOJUNG BIO Inc - Advanced Valuation Insights
This section examines the relationship between WOOJUNG BIO Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.86 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -3.7% |
| Total Assets | ₩94.70 Billion |
| Market Capitalization | $28.07 Million USD |
Valuation Analysis
Below Book Valuation: The market values WOOJUNG BIO Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: WOOJUNG BIO Inc's assets decreased by 3.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for WOOJUNG BIO Inc (2016–2024)
The table below shows the annual total assets of WOOJUNG BIO Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩94.70 Billion ≈ $64.18 Million |
-3.70% |
| 2023-12-31 | ₩98.33 Billion ≈ $66.64 Million |
+3.51% |
| 2022-12-31 | ₩94.99 Billion ≈ $64.38 Million |
-5.14% |
| 2021-12-31 | ₩100.14 Billion ≈ $67.86 Million |
+43.43% |
| 2020-12-31 | ₩69.82 Billion ≈ $47.31 Million |
+21.14% |
| 2019-12-31 | ₩57.63 Billion ≈ $39.06 Million |
+28.61% |
| 2018-12-31 | ₩44.81 Billion ≈ $30.37 Million |
+42.72% |
| 2017-12-31 | ₩31.40 Billion ≈ $21.28 Million |
+161.65% |
| 2016-12-31 | ₩12.00 Billion ≈ $8.13 Million |
-- |
About WOOJUNG BIO Inc
WOOJUNG BIO, Inc. provides non-clinical research agency services. The company was founded in 1989 and is based in Hwaseong-si, South Korea.